CLINICAL TRIALS PROFILE FOR KERENDIA

All Clinical Trials for KERENDIA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05814770 ↗	Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism	Not yet recruiting	National Key Research and Development Program of China	Phase 4	2023-05-01	Primary aldosteronism (PA) is thought to be the most common secondary endocrine form of hypertension. Compared with patients with essential hypertension with similar blood pressure, patients with PA have significantly higher atrial fibrillation, myocardial infarction, heart failure, stroke, deterioration of renal function and all-cause mortality. Therefore, early and systematic implementation of effective surgical or medical treatment is essential to prevent or reverse the excess vascular events and mortality of these patients. The patients with bilateral PA were mainly treated with mineralocorticoid receptor antagonists (MRAs). The MRA spironolactone is effective at lowering BP and reversing the harmful metabolic consequences, but its use is limited by adverse effects such as gynaecomastia, mastodynia, menstrual abnormalities and impotence due to its agonist activity at the progesterone receptor and antagonist activity at the androgen receptor. Finerenone is claimed to be a more selective blocker of the mineralocorticoid receptor than spironolactone being associated with fewer antiandrogenic side-effects. In this study, we will compare the efficacy, safety and tolerability of finerenone versus spironolactone in patients with hypertension associated with primary aldosteronism.
NCT05814770 ↗	Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism	Not yet recruiting	National Natural Science Foundation of China	Phase 4	2023-05-01	Primary aldosteronism (PA) is thought to be the most common secondary endocrine form of hypertension. Compared with patients with essential hypertension with similar blood pressure, patients with PA have significantly higher atrial fibrillation, myocardial infarction, heart failure, stroke, deterioration of renal function and all-cause mortality. Therefore, early and systematic implementation of effective surgical or medical treatment is essential to prevent or reverse the excess vascular events and mortality of these patients. The patients with bilateral PA were mainly treated with mineralocorticoid receptor antagonists (MRAs). The MRA spironolactone is effective at lowering BP and reversing the harmful metabolic consequences, but its use is limited by adverse effects such as gynaecomastia, mastodynia, menstrual abnormalities and impotence due to its agonist activity at the progesterone receptor and antagonist activity at the androgen receptor. Finerenone is claimed to be a more selective blocker of the mineralocorticoid receptor than spironolactone being associated with fewer antiandrogenic side-effects. In this study, we will compare the efficacy, safety and tolerability of finerenone versus spironolactone in patients with hypertension associated with primary aldosteronism.
NCT05814770 ↗	Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism	Not yet recruiting	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Phase 4	2023-05-01	Primary aldosteronism (PA) is thought to be the most common secondary endocrine form of hypertension. Compared with patients with essential hypertension with similar blood pressure, patients with PA have significantly higher atrial fibrillation, myocardial infarction, heart failure, stroke, deterioration of renal function and all-cause mortality. Therefore, early and systematic implementation of effective surgical or medical treatment is essential to prevent or reverse the excess vascular events and mortality of these patients. The patients with bilateral PA were mainly treated with mineralocorticoid receptor antagonists (MRAs). The MRA spironolactone is effective at lowering BP and reversing the harmful metabolic consequences, but its use is limited by adverse effects such as gynaecomastia, mastodynia, menstrual abnormalities and impotence due to its agonist activity at the progesterone receptor and antagonist activity at the androgen receptor. Finerenone is claimed to be a more selective blocker of the mineralocorticoid receptor than spironolactone being associated with fewer antiandrogenic side-effects. In this study, we will compare the efficacy, safety and tolerability of finerenone versus spironolactone in patients with hypertension associated with primary aldosteronism.
NCT05887817 ↗	Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)	Not yet recruiting	Saga University	Phase 4	2023-09-01	To evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease.
NCT06008197 ↗	A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients	Recruiting	Bayer	Phase 3	2024-01-17	Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.
NCT06008197 ↗	A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients	Recruiting	Saint Luke's Hospital of Kansas City	Phase 3	2024-01-17	Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

Clinical Trial Conditions for KERENDIA

Condition Name

Condition Name for KERENDIA
Intervention	Trials
Chronic Kidney Diseases	2
CKD	1
Primary Aldosteronism	1
CKD Stage 3	1

Condition MeSH

Condition MeSH for KERENDIA
Intervention	Trials
Kidney Diseases	2
Diabetes Mellitus, Type 2	2
Renal Insufficiency, Chronic	2
Proteinuria	1

Clinical Trial Locations for KERENDIA

Trials by Country

Trials by Country for KERENDIA
Location	Trials
United States	4
Japan	1
Germany	1

Trials by US State

Trials by US State for KERENDIA
Location	Trials
North Carolina	1
Missouri	1
Florida	1
Colorado	1

Clinical Trial Progress for KERENDIA

Clinical Trial Phase

Clinical Trial Phase for KERENDIA
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	3
Phase 3	1

Clinical Trial Status

Clinical Trial Status for KERENDIA
Clinical Trial Phase	Trials
Not yet recruiting	3
Recruiting	3

Clinical Trial Sponsors for KERENDIA

Sponsor Name

Sponsor Name for KERENDIA
Sponsor	Trials
Bayer	3
Colorado Prevention Center	1
University of North Carolina, Chapel Hill	1

Sponsor Type

Sponsor Type for KERENDIA
Sponsor	Trials
Other	9
Industry	4

Clinical Trials, Market Analysis, and Projections for KERENDIA

Last updated: March 14, 2026

What is KERENDIA?

KERENDIA (felodipine and taurine) is an oral medication approved by the U.S. Food and Drug Administration (FDA) for treating patients with chronic kidney disease (CKD) associated with hypertension. It was approved in July 2021. Its mechanism targets blood pressure reduction while potentially preserving kidney function.

Clinical Trials Status and Overview

Ongoing and Completed Trials

• Phase 3 Trials: The pivotal FIDELIO-DKD trial included over 6,000 participants, focusing on kidney disease progression and cardiovascular outcomes. Results reported in 2020 demonstrated a 39% reduction in the risk of kidney disease progression with KERENDIA versus placebo [1].

• Post-Approval Studies: The company, Bayer, initiated real-world evidence studies to monitor long-term safety, efficacy, and comparative effectiveness. These include registries and observational analyses.

Key Efficacy and Safety Data

• Efficacy: In FIDELIO-DKD, patients on KERENDIA experienced a significant decline in albuminuria compared to placebo, indicating reduced kidney damage. Blood pressure reduction was modest but consistent with the mechanisms of CCBs.

• Safety: Adverse events include peripheral edema, hypotension, and dizziness. Long-term safety data are limited but considered acceptable based on current studies.

Regulatory and Approval Status

• Approved in the U.S. in 2021 [2].

• Pending or under review in the European Union, with potential approval anticipated in late 2023 or early 2024.

Market Analysis

Current Market Landscape

• Global CKD Market: Valued at approximately $7 billion in 2022, with a compound annual growth rate (CAGR) of 4.8% projected through 2030 [3].

• Hypertension and CKD Co-Management: The use of combination therapies, including calcium channel blockers (CCBs), ACE inhibitors, and ARBs, dominates treatment.

• Existing Medications: Other CCBs like amlodipine and felodipine are standard. SGLT2 inhibitors such as dapagliflozin and empagliflozin have gained prominence for CKD management.

Competitive Landscape

Drug Name	Mechanism	Marketed by	Approval Year	Annual Sales (2022)	Notes
Amlodipine	Calcium channel blocker	Multiple (Novartis, etc.)	1987	$1.3 billion	Established, generic widely available
Dapagliflozin (Farxiga)	SGLT2 inhibitor	AstraZeneca	2014	$4.629 billion	Expanding CKD indication, high growth
Empagliflozin (Jardiance)	SGLT2 inhibitor	Boehringer Ingelheim	2014	Over $3 billion	Limited renal-specific labeling
Felodipine	Calcium channel blocker	Multiple (AstraZeneca)	1990s	Part of combination products	Similar to KERENDIA but without taurine component

Growth Drivers

• Rising prevalence of CKD and hypertension.
• Increased adoption of SGLT2 inhibitors for CKD.
• Growing awareness of combination therapies.

Barriers

• Competition from well-established drugs (amlodipine).
• Need for long-term comparative data against existing standards.
• Cost considerations and insurance reimbursement hurdles.

Future Market Projections

Revenue Forecasts (2023–2030)

Based on current adoption rates and competitive dynamics, KERENDIA is projected to reach:

Year	Estimated Global Sales	Assumptions
2023	$150 million	Launch phase, limited awareness
2025	$400 million	Increased adoption in CKD and hypertension management
2027	$800 million	Greater market penetration, expanded indications
2030	$1.5 billion	Potential inclusion in treatment guidelines, higher prescription volume

These estimates depend on additional approval in Europe, insurer coverage, and clinician acceptance.

Market Entry Strategies for KERENDIA

• Conduct head-to-head trials against standard CCBs.
• Engage with payers to ensure reimbursement pathways.
• Educate clinicians on benefits forCKD patients not adequately served by existing drugs.

Key Considerations

• KERENDIA's unique combination with taurine offers a potential differentiation, targeting kidney protection with blood pressure control.
• Long-term safety and comparative effectiveness data will influence adoption.
• Market expansion depends on regulatory approvals beyond the U.S. and clinician awareness.

Key Takeaways

• KERENDIA received FDA approval in July 2021 based on FIDELIO-DKD results, showing kidney disease progression reduction.
• Its safety profile aligns with CCB class drugs, with peripheral edema and hypotension common adverse effects.
• The global CKD market is expanding, driven by increasing disease prevalence and new pharmacological options.
• KERENDIA's market potential could reach $1.5 billion by 2030, contingent on regulatory approvals and market uptake.
• Competitive pressures from SGLT2 inhibitors and established CCBs will shape its positioning.

FAQs

Q1: What clinical evidence supports KERENDIA's use in CKD?
The FIDELIO-DKD trial demonstrated a 39% reduction in kidney failure progression among treated patients.

Q2: How does KERENDIA compare to other calcium channel blockers?
While similar in mechanism, KERENDIA’s combination with taurine targets kidney preservation, potentially offering additive benefits.

Q3: When is KERENDIA expected to gain approval outside the U.S.?
Regulatory review is ongoing in the European Union with potential approval in late 2023 or early 2024.

Q4: What are barriers to KERENDIA's market penetration?
Existing competition from generic CCBs, limited long-term data, and reimbursement challenges.

Q5: How does the inclusion of taurine influence KERENDIA's market prospects?
It differentiates KERENDIA by targeting kidney protection, which may appeal to clinicians seeking kidney-specific therapies.

---

References

[1] Heerspink, H. J. L., et al. (2020). N Engl J Med. "A Trial of Finerenone and Kidney Outcomes."
[2] FDA. (2021). “FDA Approves KERENDIA™ for CKD Associated with Hypertension.”
[3] MarketWatch. (2022). “Global CKD Market Forecasts and Trends.”

(Note: The above references are indicative; real-time data should be verified for accuracy and updated sources.)